Do you need to accelerate antibody discovery ?

The novel ETx-22, a nectin-4-targeting antibody-drug conjugate (ADC), addresses limitations of existing ADCs, like enfortumab vedotin (EV). Leveraging the Beacon Optofluidic system, it becomes possible to select antibodies targeting nectin-4-expressing tumor cells with minimal keratinocyte binding. Humanized and conjugated to an advanced linker and exatecan, ETx-22 shows strong in vitro and in vivo antitumor efficacy, including in EV-resistant and low-nectin-4 models, suggesting that ETx-22 could be a valuable therapy to treat patients whose urothelial cancer has progressed on EV therapy.

Send